Speaker illustration

Doctor Samuel Dagogo-Jack

Memphis (United States of America)

Envisioning the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease: a roundtable discussion.

Event: ESC Congress 2018

Topic: Cardiovascular Disease in Special Populations

Session: Five things cardiologists should know about diabetes

Thumbnail

Questions & Answers.

Event: ESC Congress 2018

Topic: Cardiovascular Disease in Special Populations

Session: Five things cardiologists should know about diabetes

Thumbnail

Ertugliflozin – A newly emerging SGLT2 inhibitor for patients with type 2 diabetes.

Event: ESC Congress 2018

Topic: Cardiovascular Disease in Special Populations

Session: Five things cardiologists should know about diabetes

Thumbnail

ESC 365 is supported by

logo Novo Nordisk